Attached files
file | filename |
---|---|
8-K - PRIMARY DOCUMENT - Medite Cancer Diagnostics, Inc. | mdit8k_feb162017.htm |
EXHIBIT
99.1
Press
Release
Orlando, FL.,
February 23, 2017 – MEDITE Cancer Diagnostics, Inc. (OTCQB:
MDIT, “MEDITE” or the “Company”) today
announced that Eric M. Goehausen has been elected to MEDITE’s
Board of Directors.
Mr. Goehausen has been the managing member of New Harbor Merchant
Partners, a private family
investment office that invests in growth-oriented businesses and
special situations since 2003. Mr. Goehausen also currently serves
as the Director of Revenue Growth of the Clinical Solutions Team of
Anthem, Inc., a Fortune 30 company.
Mr. Goehausen has more than 17 years of corporate advisory, CFO and
executive-level financial management responsibilities, having led
all facets of financial operations including financial, planning
and analysis; accounting; treasury; profit improvement; M&A
activity; bank and Board reporting and compliance; restructuring
and transformational events for private-equity owned and public
companies ranging from $100M to $4B in revenue.
Mr. Goehausen started his career in investment banking with
JPMorgan Chase in 1998, where he focused on mergers, acquisitions,
leveraged buyouts, and corporate financings. In 2003, Eric
formed New Harbor Merchant Partners, a private investment firm
focused on providing strategic capital and advisory services to
middle market companies and business leaders. He served the global
professional law firm of Kirkland & Ellis, LLP in a corporate
finance and investment banking advisory role; served as the interim
Vice President of Finance and Accounting for a private
equity-controlled $120 million consumer products distribution
business; and advised a privately-held $190 million facilities
management company through its refinancing, and profit and
operational improvement process.
During 2006 through 2011, Mr. Goehausen was with the global
professional services firm Alvarez & Marsal where he focused on
restructuring, turnaround advisory and interim management of
private equity controlled and public companies with revenue ranging
from $100 million to $4 billion, and has served in interim CFO
capacities of businesses with revenues of $200M to $500M. Mr.
Goehausen was then Vice President of Corporate Development for a
publicly-traded dental products manufacturing company prior to its
sale, and subsequently Chief Financial Officer of a private equity
controlled education management company.
Mr.
Goehausen earned his Master of Business Administration, With
Honors, from The University of Chicago Booth School of Business
with concentrations in Accounting, Finance and Entrepreneurship,
and earned his Bachelor of Science in Business with a major in
Finance, Cum Laude, from Miami University in Oxford, OH. He
has completed advanced studies in Corporate Finance and
International Securities Markets at the London School of Economics,
as well as Financial Markets, Institutions and Money & Banking
at Northwestern University, and holds his CIRA
certification.
Mr.
Goehausen has served on the Board of Managers of American EMS, LLC,
and as a board observer to Primaria Health, LLC and Precision Parts
International, Inc.
About MEDITE Cancer Diagnostics, Inc.
MEDITE
Cancer Diagnostics Inc., is a Delaware registered company
consisting of wholly-own MEDITE GmbH a Germany-based company with
its subsidiaries. On April 3, 2014, MEDITE was acquired by former
CytoCore, Inc. a biomolecular diagnostics company engaged in the
design, development, and commercialization of cost-effective cancer
screening systems and Biomarkers to assist in the early detection
of cancer. By acquiring MEDITE the company changed from solely
research operations to an operating company with a well-developed
infrastructure, 80 employees in four countries, a distribution
network to about 70 countries worldwide, a well-known and
established brand name and a wide range of products for anatomic
pathology, histology and cytology laboratories.
Forward Looking Statement
This
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
regarding future operating performance, events, trends and plans.
All statements other than statements of historical fact contained
herein, including, without limitation, statements regarding our
future financial position, business strategy, budgets, projected
revenues and costs, and plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,”
“will,” “expects,” “intends,”
“plans,” “projects,”
“estimates,” “anticipates,” or
“believes” or the negative thereof or any variation
thereon or similar terminology or expressions. We have based these
forward-looking statements on our current expectations and
projections about future events. These forward-looking statements
are not guarantees and are subject to known and unknown risks,
uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause our
actual results to differ from our expectations, include but are not
limited to, MEDITE’s ability to maintain and grow its
revenues. Readers are cautioned not to place undue reliance on our
forward-looking statements, as they speak only as of the date made.
Such statements are not guarantees of future performance or events
and we undertake no obligation to disclose any revision to these
forward-looking statements to reflect events or circumstances
occurring after the date hereof.
For more information please
visit: www.medite-group.com
Investor Contact:
David
E, Patterson
Chief
Executive Officer
407 996
9630